RAFE - ETF AI Analysis
Top Page
PIMCO RAFI ESG U.S. ETF (RAFE)
Rating:72Outperform
Price Target:―
Positive Factors
Broad Sector Diversification
The fund spreads its investments across many sectors, with meaningful stakes in technology, health care, financials, and consumer stocks, which helps reduce reliance on any single industry.
Supportive Recent Performance
The ETF has shown positive performance over the past month, three months, and year to date, indicating recent upward momentum.
Several Strong Top Holdings
Key positions in companies like Johnson & Johnson, UnitedHealth, Merck, Citigroup, Verizon, and AT&T have been performing well so far this year, helping support the fund’s overall returns.
Negative Factors
Heavy U.S. Concentration
With almost all assets invested in U.S. companies, the fund offers very limited geographic diversification and is highly tied to the U.S. market.
Mixed Performance Among Largest Stocks
Some major holdings such as Apple, Microsoft, JPMorgan Chase, and Procter & Gamble have been weak this year, which can drag on the ETF’s results if that trend continues.
Moderate Expense Ratio
The fund’s expense ratio is not especially low for a U.S. equity ETF, meaning fees take a somewhat larger bite out of returns compared with the cheapest index funds.
RAFE vs. SPDR S&P 500 ETF (SPY)
AUM138.76M
RegionNorth America
Expense Ratio0.29%
Beta0.83
IssuerPIMCO
Inception DateDec 18, 2019
Dividend Yield1.61%
Asset ClassEquity
Index TrackedRAFI ESG US Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,443
30 Day Avg. Volume14,965
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
50.27Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering283
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RAFE Summary
The PIMCO RAFI ESG U.S. ETF (RAFE) is a fund that tracks the RAFI ESG US Index, aiming to cover most of the U.S. stock market while focusing on companies that meet certain environmental, social, and governance (ESG) standards. It holds a wide mix of large, mid, and small U.S. companies, including well-known names like Apple and Microsoft, plus major health care and financial firms. Someone might invest in this ETF to get broad diversification in U.S. stocks while trying to support more responsible businesses. A key risk is that its value can rise and fall with the overall stock market and with trends in ESG investing.
How much will it cost me?The PIMCO RAFI ESG U.S. ETF (RAFE) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed and incorporates ESG criteria, which require more research and oversight compared to passively managed funds. It’s a good option if you value sustainable investing and are comfortable with the slightly higher cost.
What would affect this ETF?The PIMCO RAFI ESG U.S. ETF could benefit from growing interest in ESG investing and the strong performance of its top holdings in technology and healthcare, sectors that often thrive during innovation and demographic shifts. However, potential risks include regulatory changes affecting ESG criteria, economic downturns impacting consumer spending, or rising interest rates that could pressure financial and cyclical sectors. Its focus on U.S. equities also makes it sensitive to domestic economic conditions and policy changes.
RAFE Top 10 Holdings
RAFE leans heavily into U.S. tech and health care, with Apple and Microsoft acting as key swing factors: Apple has been rising again after a soft start to the year, while Microsoft’s recent moves have been more mixed, keeping its impact in check. On the defensive side, steady names like Johnson & Johnson and Merck are quietly supporting the fund, and UnitedHealth has been a bright spot lately. Big banks and telecoms such as JPMorgan and Verizon add diversification, but they’re more background players than headline drivers right now.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Apple | 5.16% | $7.06M | $3.98T | 27.35% | 79 Outperform | |
| Microsoft | 4.16% | $5.69M | $3.15T | 8.60% | 79 Outperform | |
| Johnson & Johnson | 3.42% | $4.68M | $547.64B | 45.05% | 78 Outperform | |
| UnitedHealth | 3.14% | $4.30M | $322.15B | -15.55% | 72 Outperform | |
| JPMorgan Chase | 2.54% | $3.47M | $831.44B | 28.13% | 72 Outperform | |
| Merck & Company | 2.25% | $3.08M | $276.38B | 32.50% | 80 Outperform | |
| Verizon | 2.18% | $2.98M | $195.62B | 11.11% | 81 Outperform | |
| Citigroup | 2.17% | $2.96M | $219.47B | 89.13% | 68 Neutral | |
| AT&T | 2.13% | $2.91M | $182.97B | -6.38% | 71 Outperform | |
| Procter & Gamble | 2.00% | $2.74M | $344.37B | -8.31% | 69 Neutral |
RAFE Technical Analysis
Positive
―
Price Trends
42.62
Positive
42.52
Positive
41.03
Positive
Market Momentum
0.56
Negative
65.25
Neutral
50.26
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RAFE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 43.26, equal to the 50-day MA of 42.62, and equal to the 200-day MA of 41.03, indicating a bullish trend. The MACD of 0.56 indicates Negative momentum. The RSI at 65.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAFE.
RAFE Peer Comparison
Comparison Results
Performance Comparison
RAFE
PIMCO RAFI ESG U.S. ETF
44.02
9.43
27.26%
SYLD
Cambria Shareholder Yield ETF
―
―
―
AUSF
Global X Adaptive U.S. Factor ETF
―
―
―
ULTY
YieldMax Ultra Option Income Strategy ETF
―
―
―
FDMO
Fidelity Momentum Factor ETF
―
―
―
HLAL
Wahed FTSE USA Shariah ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents